RT info:eu-repo/semantics/article T1 Hospitalized COVID-19 patients with severe acute respiratory syndrome: A population-based registry analysis to assess clinical findings, pharmacological treatment and survival A1 Gutiérrez Abejón, Eduardo A1 Herrera Gómez, Francisco Magno A1 Pedrosa Naudín, M. Aránzazu A1 Tamayo Gómez, Eduardo A1 Álvarez González, Francisco Javier K1 SARS-CoV-2 K1 COVID-19 K1 SARS (Disease) K1 Syndromes K1 Clinical findings K1 Pharmacotherapy K1 Survival K1 Supervivencia K1 Virology K1 3209 Farmacología K1 32 Ciencias Médicas K1 2420 Virología AB Background and Objectives: One of the most serious clinical outcomes in hospitalized patients with COVID-19 is severe acute respiratory syndrome (SARS). The aim is to analyze pharmacological treatment, survival and the main mortality predictors. Materials and Methods: A real-world data study from COVID-19-hospitalized patients with SARS from 1 March to 31 May 2020 has been carried out. Variables such as hospital length of stay, ventilation type and clinical outcomes have been taken into account. Results: In Castile and Leon, 14.03% of the 7307 in-hospital COVID-19 patients developed SARS, with a mortality rate of 42.53%. SARS prevalence was doubled in males compared to females, and 78.54% had an age of 65 years or more. The most commonly used medicines were antibiotics (89.27%), antimalarials (68.1%) and corticosteroids (55.9%). Survival of patients developing SARS was lower compared to patients without this complication (12 vs. 13 days). The main death predictors were disseminated intravascular coagulation (DIC) (OR: 13.87) and age (>65 years) (OR: 7.35). Conclusions: Patients older than 65 years who develop DIC have a higher probability of hospital death. Tocilizumab and steroids have been linked to a lower incidence of hospital death, being the main treatment for COVID-19 hospitalized patients with SARS. PB MDPI SN 1648-9144 YR 2022 FD 2022 LK https://uvadoc.uva.es/handle/10324/61877 UL https://uvadoc.uva.es/handle/10324/61877 LA eng NO Medicina, 2022, Vol. 58, Nº. 6, 829 NO Producción Científica DS UVaDOC RD 12-sep-2024